Decline of RSV-specific antibodies during the COVID-19 pandemic

Lancet Infect Dis. 2023 Jan;23(1):23-25. doi: 10.1016/S1473-3099(22)00763-0. Epub 2022 Dec 1.

Authors

Gerco den Hartog¹, Puck B van Kasteren², Rutger M Schepp², Anne C Teirlinck², Fiona R M van der Klis², Robert S van Binnendijk²

Affiliations

¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, 3721 Bilthoven, Netherlands. Electronic address: gerco.den.hartog@rivm.nl.
² Center for Infectious Disease Control, National Institute for Public Health and the Environment, 3721 Bilthoven, Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
COVID-19*
Humans
Pandemics
Respiratory Syncytial Virus Infections* / epidemiology
Respiratory Syncytial Virus, Human*

Substances

Antibodies, Neutralizing